arrow_back Back to App

Boosting COVID-19 Vaccine and Treatment Production

This act aims to increase the availability of vaccines, treatments, and medical supplies essential for combating COVID-19. It allocates funding for the research, development, and procurement of these products, intending to accelerate a return to normalcy and protect public health. Citizens can expect faster access to necessary medical resources.
Key points
Allocating $20 billion for fiscal years 2021-2025 to develop and manufacture COVID-19 vaccines and treatments.
Expanding domestic production capacity to ensure sufficient supply of vaccines and therapeutics for citizens.
Supporting the manufacturing of essential medical supplies like syringes, needles, and personal protective equipment.
Requiring reports on production and distribution progress to ensure transparency and efficiency.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_349
Sponsor: Rep. Kuster, Ann M. [D-NH-2]
Process start date: 2021-01-19
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Coronavirus Vaccine and Therapeutic Development Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_349.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-19.

What are the main provisions?

Key points include:

  • Allocating $20 billion for fiscal years 2021-2025 to develop and manufacture COVID-19 vaccines and treatments.
  • Expanding domestic production capacity to ensure sufficient supply of vaccines and therapeutics for citizens.
  • Supporting the manufacturing of essential medical supplies like syringes, needles, and personal protective equipment.
  • Requiring reports on production and distribution progress to ensure transparency and efficiency.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Kuster, Ann M. [D-NH-2].

What is the latest detailed status?

The latest detailed status is: Sponsor introductory remarks on measure. (CR H393)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Public Investments